<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054533</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0899</org_study_id>
    <nct_id>NCT02054533</nct_id>
  </id_info>
  <brief_title>Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease</brief_title>
  <acronym>PUCCINI</acronym>
  <official_title>Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understanding of how best to treat inflammatory bowel disease (IBD) has evolved over the last
      ten years. Evidence now suggests that the most effective therapy early in the course of
      Crohn's disease (CD) and ulcerative colitis (UC) involves the use of immune suppressing
      medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab,
      and certolizumab. However, many CD and UC patients still ultimately require surgery despite
      the use of these medications. Side effects of the anti-TNF agents include increased risk of
      infections due to their effect on the immune system. Little is known about how use of these
      medications near the time of surgery may affect patients' risks of infection or other
      post-operative complications. The only available studies on this topic have given conflicting
      results. These studies have been limited by the fact that they have been small in size and
      retrospective. Retrospective studies primarily involve chart review as the method of
      identifying potential risk factors for infections and other complications after they have
      already occurred. This method limits both the type and quality of information/data that can
      be collected. The conflicting results have led to variance in practice patterns with regards
      to management of anti-TNF agents, the timing of surgery, and even the types of surgery.

      By enrolling patients at the time of their surgery, collecting extensive information may be
      possible than previously studied on potential risk factors for both infectious and
      non-infectious complications following surgery. Risk factors to be studied will include
      individual patient characteristics, disease characteristics, surgical methods, novel
      characteristics of CT scans and MRIs and extensive medication exposures. The primary
      objective is to determine if exposure to anti-TNF agents prior to surgery increases the risk
      of infection post-operatively. And evaluate exposure to anti-TNF agents by both patient
      history of use and measurement of anti-TNF drug levels at the time of surgery. Monitoring of
      drug levels at the time of surgery has never been utilized in this way to evaluate the risk
      of anti-TNF agents in IBD. However, this has been done to assess the risk of other
      medications in different diseases.

      If anti-TNF agents are found to pose a risk for infectious or non-infectious outcomes in IBD
      patients undergoing surgery, change maybe needed in the way these medications are used around
      the time of surgery. Additionally, by collecting comprehensive information on other potential
      risk factors besides medication use patients at greatest risk for bad outcomes can be
      identified and take protective measures when possible. The aims of this study address the
      CCFA challenge to better define the risks of medical and surgical therapies to improve the
      quality of care of IBD patients undergoing surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational study designed to determine if
      pre-operative exposure to anti-TNF agents is an independent risk factor for post-operative
      infectious complications within 30 days of surgery in subjects with IBD.

      Patient Assessments:

      Patient assessments will occur at the Screening/Baseline Visit, Discharge Day, and 30-Day
      Telephone Follow-up (see Figure 1). Potential pre-operative predictors of post-operative
      infections will be assessed at the Screening/Baseline Visit through a brief patient interview
      and abstraction of medical records. Data will be entered into the electronic case report
      forms (eCRF). A second data abstraction will occur on the Discharge Day. At this time, all
      data from the day of surgery will be available including finalized operative reports,
      anesthesia records, and pathology. The post-operative medical record will also be reviewed
      for potential confounding factors related to post-operative infection (i.e. presence of
      central lines, foley catheters, antibiotic use, etc.). Additionally, the medical record will
      be reviewed for the occurrence of post-operative infection and the other non-infectious
      outcomes being studied. Data will be entered into the eCRF. The final assessment will occur
      on post-operative day 30 (within 1 week). A telephone interview will be conducted. The
      purpose of the interview is to assess for the occurrence of post-operative infection and
      non-infectious outcomes. If an infection has been identified, relevant medical records will
      be requested to confirm infection and abstract information pertaining to the infection. Data
      will be entered into the eCRF.

      Assessment of Anti-TNF Exposure:

      Exposure to anti-TNF agents will be defined in two different ways. The primary analysis will
      define anti-TNF exposure as patient report of use within 12 weeks of surgery pre-operatively.
      Confirmation of patient report will be through medical record abstraction. This definition of
      anti-TNF exposure is consistent with many of the retrospective, single center studies on
      post-operative infections related to IBD surgery. The 12-week cutoff point has been chosen to
      account for the washout of infliximab before surgery based on its half-life. However, the
      different anti-TNF agents have varying half-lives. Date of last administration prior to
      surgery will be recorded so that different cutoff points to define exposure such as 4 weeks
      and 8 weeks may be explored.

      The secondary analysis will define anti-TNF exposure by measured peri-operative levels in
      patients with a history of anti-TNF use in the six months preceding surgery. Anti-TNF levels
      and anti-drug antibodies will be checked at two time points in patients with recent anti-TNF
      use. An initial level will be drawn at the screening visit, which may occur peri-operatively
      up to post-op day 4. A second level will be drawn anytime between post-op day 4 and post-op
      day 7. The serum from these blood draws will be stored at -80 Celsius until the third year of
      the study at which time samples will be tested for drug levels and antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Infection</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pouch Specific Complication</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Anastomotic Leaks
Pelvic Abscesses
Pouch fistula
Pouch dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital re-admission</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation secondary to surgical complication</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of post-operative hospitalization</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day post-operative mortality</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic complication</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypomotility complication</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">974</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>IBD patients</arm_group_label>
    <description>patients with IBD undergoing intra-abdominal surgery</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with IBD undergoing intra-abdominal surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older;

          -  Diagnosis of CD, UC, or indeterminate colitis by standard criteria;

          -  Patient planned to have intra-abdominal surgery or has had intra-abdominal surgery in
             the preceding four days;

          -  Ability to provide written informed consent.

        Exclusion Criteria:

          -  Current enrollment in a clinical trial for an investigational IBD therapy;

          -  Surgery to repair a complication from a recent surgery (â‰¤ 90 days);

          -  Inability or unwillingness to provide written informed consent;

          -  Any other condition which may impede competence or compliance or hinder completion of
             the study in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Sands, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburth</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Surgery</keyword>
  <keyword>Anti-Tumor Necrosis Factor</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

